Egyptian International Pharmaceutical Investments (CAI:PHAR) Revenue per Share : E£37.52 (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Revenue per Share?

Egyptian International Pharmaceutical Investments's revenue per share for the three months ended in Dec. 2023 was E£10.42. Egyptian International Pharmaceutical Investments's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was E£37.52.

During the past 12 months, the average Revenue Per Share Growth Rate of Egyptian International Pharmaceutical Investments was 14.60% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 15.60% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 8.90% per year. During the past 10 years, the average Revenue Per Share Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Egyptian International Pharmaceutical Investments's Revenue per Share or its related term are showing as below:

CAI:PHAR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.1 Med: 10.05 Max: 20.8
Current: 15.6

During the past 13 years, Egyptian International Pharmaceutical Investments's highest 3-Year average Revenue Per Share Growth Rate was 20.80% per year. The lowest was 5.10% per year. And the median was 10.05% per year.

CAI:PHAR's 3-Year Revenue Growth Rate is ranked better than
76.81% of 923 companies
in the Drug Manufacturers industry
Industry Median: 6.4 vs CAI:PHAR: 15.60

Egyptian International Pharmaceutical Investments Revenue per Share Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Revenue per Share Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Revenue per Share

Get a 7-Day Free Trial

26.46

22.75

26.44

30.68

35.17

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Revenue per Share	Get a 7-Day Free Trial															9.84	7.70	9.91	9.49	10.42

Competitive Comparison of Egyptian International Pharmaceutical Investments's Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egyptian International Pharmaceutical Investments's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's PS Ratio distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's PS Ratio falls into.

Egyptian International Pharmaceutical Investments Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Egyptian International Pharmaceutical Investments's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )	=	Revenue (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	5231.666	/	148.756
	=	35.17

Egyptian International Pharmaceutical Investments's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )	=	Revenue (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	1550.576	/	148.756
	=	10.42

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was E£37.52

Egyptian International Pharmaceutical Investments (CAI:PHAR) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Egyptian International Pharmaceutical Investments Revenue per Share Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.